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Background: Reports of pulmonary edema complicating inhaled nitric oxide 
therapy in patients with chronic heart failure and pulmonary hypertension 
have raised the concern that inhaled nitric oxide may have negative 
inotropic effects. Methods and results: We investigated the effect of multiple 
doses of inhaled nitric oxide (20, 40 and 80 ppm) on left ventricular 
contractile state in 10 open-chest pigs. Pressure-volume loops were gener- 
ated during transient preload reduction to determine the end-systolic 
pressure-volume relationship and the stroke work-end-diastolic volume 
relation. Inhaled nitric oxide had no effect on systemic vascular resistance, 
cardiac output, end-systolic pressure-volume relationship or stroke work- 
end-diastolic volume relation under normal conditions. After induction of 
pulmonary hypertension (intravenous thromboxane Az analog), inhalation 
of nitric oxide (80 ppm) resulted in a reduction in pulmonary vascular 
resistance (mean -- standard error of the mean) from 10.4 -- 3 to 6.5 - 2 
Wood units (p < 0.001) and in pulmonary artery pressure from 44 - 4 to 
33 -- 4 mm Hg (p < 0.05). Left ventricular end-diastolic volume rose from 
53 -- 9 ml to 57 -- 10 ml (p = 0.02). No statistically significant change in 
cardiac output or systemic vascular resistance was observed. Inhaled nitric 
oxide had no effect on end-systolic pressure-volume relationship or stroke 
work-end-diastolic volume relation. Conclusions: In a porcine model of 
pulmonary hypertension, inhaled nitric oxide does not impair left ventric- 
ular contractile function. Therefore the cause of pulmonary edema ob- 
served in some patients receiving inhaled nitric oxide is not due to a 
negative inotropic action of this therapy. (J Thorac Cardiovasc Surg 1997; 
114:461-6) 
nhaled nitric oxide (NO) is currently being used in 
a number of clinical situations to selectively reduce 
12 pulmonary vascular esistance. ' When given by the 
inhaled route, NO reduces pulmonary vascular e- 
sistance while leaving systemic vascular resistance 
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unaltered. This selectivity is a result of the rapid 
sequestration and inactivation of NO by hemoglobin 
before NO reaches the systemic irculation. 34 How- 
ever, reports of significant increases in pulmonary 
artery wedge pressure in patients with heart failure 
receiving inhaled NO therapy 6 have raised impor- 
tant questions about this therapy. Emerging evi- 
dence that endogenous NO exerts negative inotro- 
pic effects 7-9 has led some investigators to wonder 
whether the increase in pulmonary artery wedge 
pressure is a result of negative inotropic actions of 
inhaled NO therapy, t°' 11 Because of the potential of 
inhaled NO to counteract the pulmonary vasocon- 
strictive effects of cardiopulmonary b pass, 12' 13 and 
to evaluate the reversibility of pulmonary hyperten- 
sion in cardiac transplant candidates, an under- 
standing of the mechanisms by which inhaled NO 
causes elevations in pulmonary artery wedge pres- 
sure in patients with heart failure is clinically impor- 
tant. 
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We designed this study to determine whether 
inhaled NO alters the ventricular contractile state. 
To this purpose, we studied the effect of inhaled NO 
in a porcine model of pulmonary hypertension in 
which state-of-the-art measurements of left ventric- 
ular (LV) function were collected at various concen- 
trations of inhaled NO. 
Methods 
Animals received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the Institute of Laboratory Animal Resources and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). In addition, this 
study also conforms with the position of the American 
Heart Association on Research Animal Use. 
Experimental preparation. The protocol was carried 
out in conditioned Yorkshire pigs weighing 45 to 50 kg. 
Animals were anesthetized with acepromazine (0.5 mgA:g 
intramuscularly), ketamine (20 mg/kg intramuscularly), 
and atropine (1 to 2 mg intramuscularly). The lungs were 
mechanically ventilated, and ventilatory parameters were 
adjusted to maintain normocarbia s evidenced by fre- 
quent blood gas analyses. Normothermia was maintained 
by the use of two warming blankets and a heating lamp 
when necessary. Anesthesia was maintained with isoflu- 
rune (1.5% to 2.0%) in 30% oxygen. The femoral artery 
was catheterized to monitor systemic blood pressure 
(mean arterial pressure) and to obtain samples for blood 
gas analysis. Through a midline sternotomy and longitu- 
dinal pericardiotomy, the inferior vena cava, pulmonary 
artery (PA), and ascending aorta were isolated with 
snares. Three 5F micromanometer-tipped catheters (Mil- 
lar Instruments, Inc., Houston, Tex.) were placed in the 
left atrium, right atrium, and PA through purse-string 
sutures in the atrial appendages and PA for continuous 
pressure monitoring. A 16 mm perivascular flow probe 
(Transonic System, Inc., Ithaca, N.Y.) was placed around 
the main PA. This flow probe was connected to an 
ultrasonic flowmeter that had a continuous display of 
cardiac output. A 5F Miltar micromanometer was placed 
in the right external carotid artery and advanced into the 
ascending aorta to monitor aortic pressure. A twelve- 
electrode (1.0 cm interelectrode spacing) 6F microma- 
nometer-tipped conductance catheter (Sentron, Federal 
Way, Wash.) was inserted through the left common 
carotid artery, advanced over the aortic valve into the LV, 
and positioned in the apex to measure LV volume and 
pressure. This catheter was connected to a signal condi- 
tioner (Leycom 5, Cardiodynamics, The Hague, The 
Netherlands), which provides the conductance signal used 
for assessing LV volume. This device also measures blood 
resistivity (0), which is necessary for estimation of volume. 
Blood resistivity was measured in each animal before the 
start of the experimental protocol and after changes in 
experimental conditions. Proper positioning of the con- 
ductance catheter was ensured by palpating the tip in the 
LV apex and using only segmental volume signals that 
corresponded to segments residing in the ventricular 
chamber for generation of the total volume signal. The 
total conductance signal is affected not only by the con- 
ductivity of the blood in the chamber in which the catheter 
lies, but also by conductive structures that surround the 
chamber. The contribution to the total conductance signal 
from these surrounding structures i termed parallel con- 
ductance. We determined parallel conductance by the 
hypertonic saline technique using 5 ml of 5% saline 
solution rapidly injected into the PA. TM Parallel conduc- 
tance was recalculated after any change in experimental 
conditions (i.e., induction of pulmonary hypertension, 
administration of different concentrations of NO) and 
before each measurement. 
NO administration. After endotracheal intubation, an- 
imals received amixture of oxygen and nitrogen to achieve 
an inspired fraction of oxygen of 32% to 35%. NO gas 
(800 ppm in nitrogen) (Alrco; BOC Gases, Murray Hill, 
N.J.) was delivered at concentrations of 20, 40, and 80 
ppm by titrating the amount of nitrogen downward and 
the level of NO upward so as to maintain a constant 
inspired oxygen fraction and total gas flow rate of 5 L/rain. 
The inspired concentration of NO was measured by an 
NO analyzer (Drager, Chantilly, Va.). Exhaled gases were 
scavenged and discarded to the atmosphere. 
Study protocol. In the first part of the protocol, animals 
were studied in four conditions: baseline condition and 
during three different doses (20, 40, and 80 ppm) of 
inhaled NO. Next, pulmonary hypertension was induced 
by continuous intravenous administration of a thrombox- 
ane A 2 analog (9,11-dideoxy-lla,9a-epoxymethanopros- 
taglandin F2; Sigma Chemical Co., St. Louis, Mo.) at a 
rate that resulted in a mean PA pressure of greater than 
35 mm Hg (0.07 to 0.15/zg/kg per minute). Animals were 
then restudied at the same four conditions just described. 
Data collected at each condition consisted of standard 
hemodynamic measurements a well as a series of LV 
pressure-volume loops measured before and during vena 
caval occlusion. The vena caval occlusion was limited to 10 
seconds in duration to avoid reflex responses and was 
repeated if arrhythmias occurred. Ventilation was held 
during the period of data collection. Measurements were 
made 5 minutes after reaching a steady state NO concen- 
tration. 
Data analysis. All analog signals were digitized at 200 
Hz with the use of a 12-bit analog-to-digital board (AD- 
Instruments, Milford, Mass.) and stored on a removable 
hard drive for subsequent analysis with IGOR analysis 
software (Wavemetrics Inc., Lake Oswego, Ore.). Pres- 
sures, flow, and volume data were subjected to a five-pass 
binomial smooth filter. End-diastolic pressure (EDP) was 
identified as the point just preceding the upstroke of the 
LV pressure wave. End-diastolic volume (EDV) was 
determined by the lower right hand corner of the pres- 
sure-volume loop. 15 
Two relations that describe ventricular contractile state 
were examined during vena caval occlusion; at least 7 
cardiac cycles free of arrhythmias were used for each 
analysis: 
End-systolic pressure-volume relationship (ESPVR). The 
slope and volume axis intercept of the end-systolic pres- 
sure-volume r lationship (ESPVR) were determined as in 
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Table I. Hemodynamics and LV contractile relations before induction of pulmonary hypertension (  = 10) 
Parameter Control NO 20 ppm NO 40 ppm NO 80 ppm p Value 
Hemodynamics 
CO 
MAP 
SVR 
LVEDP 
LVEDV 
PAP 
PVR 
Contractility 
ESPVR 
Mo 
SWEDV 
Vo 
5.7 ,+ 0.3 [4.9-6.5] 5.6 _+ 0.7 [4-7.2] 5.5 -+ 0.6 [4.1-6.9] 5.3 _+ 0.4 [4.4-6.2] >0.2 
68 _+ 3 [62-74] 68 +- 2 [62-73] 67 _+ 3 [61-73] 67 ,+ 3 [62-73] >0.2 
11 ,+ 1 [7-15] 12 _+ 2 [7-17] 12 _+ 2 [7-17] 12 _+ 2 [8-16] >0.2 
7 ,+ 2 [3-11] 8 -+ 1 [5-10] 8 .+ 1 [5-11] 8 -+ 1 [5-11] >0.2 
57 _+ 4 [48-66] 56 ,+ 4 [47-65] 57 _+ 4 [47-67] 56 .+ 4 [46-66] >0.2 
23 .+ 1.8 [19-27] 18 ,+ 1 [16-21] 19 +_ 1 [16-22] 19 ,+ 1 [16-22] 0.043 
2.8 _+ 0.4 [1.9-3.7] 2.1 _+ 0.3 [1.3-2.9] 2.2 ,+ 0.4 [1.3-3.2] 2.3 _+ 0.4 [1.3-3.2] >0.2 
2.6 -+ 0.5 2.9 ,+ 0.5 2.6 -+ 0.6 2.8 ,+ 0.6 >0.2 
-1  "+ 9 5 -+ 8 -1  -+ 9 -1  -+ 10 >0.2 
61 -+ 6 57 "+ 6 56 -+ 6 58 + 6 
27 -+ 8 26 -+ 7 26 -+ 8 26 -+ 8 >0.2 
Figures are expressed asmean -+ standard error of the mean. Brackets indicate 95% confidence intervals. CO, Cardiac output (L/min); MAP, mean arterial 
pressure (mm Hg); SVR, systemic vascular resistance (Wood units); LVEDP, left ventricular end-diastolic pressure (ram Hg); LVEDV, left ventricular 
end-diastolic volume; PAP, pulmonary artery pressure (mm Hg); PVR, pulmonary vascular resistance; ESPVR, end-systolic pressure-volume relation (mm 
Hg/ml); Mo, x-axis intercept of ESPVR line (ml); SWEDV, stroke-work end-diastolic volume (erg • cm -3 - 103) ;  No, x-axis intercept of SWEDV line (ml). 
previous tudies.15 In brief, the volume axis intercept (Vo) 
was initially assumed to be 0 ml and values for end-systolic 
pressure and end-systolic volume were determined for 
each cardiac cycle by identifying the point at which the 
value of P(t)/(V[t] - Vo) reached a maximum. Regression 
analysis of these end-systolic pressure and end-systolic 
volume points provided an improved estimate of volume 
axis intercept. This updated volume axis intercept value 
was then substituted into the equation, and new values for 
end-systolic pressure and volume were obtained. Subse- 
quent iterations were performed until the value of volume 
axis intercept changed by less than 2 ml. 
Stroke work-end-diastolic volume relationship 
(SWEDV). Stroke work was determined for each cardiac 
cycle by calculating the area within the respective pres- 
sure-volume loop. Stroke work-end-diastolic volume 
(SWEDV) was defined by the relationship between stroke 
work and end-diastolic volume. 16 
Cardiac output was determined by the integral of the 
PA flow waveform, and pulmonary and systemic vascular 
resistances were calculated by means of standard formu- 
las. 
Statistical analysis. Statistical analyses were per- 
formed with InStat software package for Macintosh on an 
Apple computer (Apple Computer, Cupertino, Calif.). 
Each relation (ESPVR, SWEDV) was described by a 
slope and a volume axis intercept obtained from linear 
regression analysis. The effect of NO on these two vari- 
ables was assessed by analysis of variance. The impact of 
NO dose on standard hemodynamic parameters was also 
assessed by analysis of variance for repeated measures. 
The Bonferroni correction was applied to account for the 
fact that comparisons were made between multiple 
groups. A two-tailed p value < 0.05 was considered 
statistically significant. 
Results 
Hemodynamic  data measured  at basel ine and at 
each NO dose (n -- 10) be fore  the induct ion  o f  
pu lmonary  hyper tens ion  are presented  in Tab le  I. 
No change was observed in cardiac output, systemic 
vascular esistance, mean arterial pressure, or left 
ventricular end-diastolic pressure (LVEDP) or vol- 
ume (LVEDV). Inhaled NO (all three doses) 
caused a slight reduction in PA pressure (mean + 
standard error of the mean) (23 _+ 1.8 mm Hg [19 to 
27 mm Hg, 95% CI*] to 19 _+ 1 mm Hg [16 to 22 mm 
Hg, 95% CI]; p = 0.04). Representative pressure- 
volume loops obtained uring transient vena caval 
occlusion at baseline and during NO administration 
are shown in Fig. 1. At each dose of NO, the 
pressure-volume loops are superimposable with 
those measured at baseline (lefipanel). The contrac- 
tile relations (ESPVR and SWEDV) derived from 
these loops were similarly unchanged by the admin- 
istration of NO (Table I and Fig. 1, right panel). 
Administration of thromboxane A2 analog re- 
sulted in an unstable preparation resulting from 
arrhythmias, severe systemic hypotension (mean ar- 
terial pressure < 40 mm Hg), or death in four 
animals; these animals were excluded from further 
study. In the remaining six animals, administration 
of thromboxane r sulted in an elevation (mean _+ 
standard error of the mean) of baseline pulmonary 
vascular esistance from 2.8 -- 0.4 Wood units (1.9 
to 3.5 Wood units, 95% CI) to 10.4 _+ 3 Wood units 
(2.9 to 17.8 Wood units, 95% CI) (p = 0.037), 
elevation of mean PA pressure from 23 _+ 2 mm Hg 
(20 to 27 mm Hg, 95% CI) to 43 _+ 4 mm Hg (35 to 
53 mm Hg, 95% CI) (p = 0.0011), and a reduction 
in cardiac output from 5.8 _+ 0.5 L/min (2.2 to 6.7, 
95% CI) to 4.5 _+ 0.9 L/min (4.4 to 7.1, 95% CI) (p = 
*CI = Confidence interval. 
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Fig. 1. Representative pressure-volume loops btained uring transient vena caval occlusion at baseline 
and during inhaled NO administration are shown. At each dose of NO (20, 40, 80 ppm), the pressure 
volume loops are superimposable with those measured at baseline (left panel). The contractile relations 
(ESPVR and SWEDV) derived from these loops were similarly unchanged by the administration f NO 
(right panel). ESPVR, End-systolic pressure-volume relation; PRSW, preload recruitable stroke work; LVP, 
left ventricular pressure; LVV,, left ventricular volume; SW, stroke work; EDV, end-diastolic volume. 
Table II. Hemodynamics and LV  standard error of the mean contractile relations after induction of 
pulmonary hypertension (n = 6) 
Pulmonary 
Parameter hypertension NO 20 ppm NO 40 ppm NO 80 ppm p Value 
Hemodynamics 
CO 4.6 _+ 1 [1.6-7.5] 4.9 _+ 1 [2.1-7.8] 5.1 +_ 1 [2.3-7.9] 5.0 _+ 1 [2-7.9] >0.2 
MAP 72 _+ 7 [52-92] 80 _+ 6 [64-97] 78 +_ 5 [65-92] 79 -+ 6 [62-96] >0.2 
SVR 20 _+ 6 [3-37] 19 _+ 6 [3-34] 17 _+ 4 [5-29] 18 _+ 5 [5-31] 0.15 
LVEDP 8 -+ 2 [3-13] 10 _+ 2 [5-15] 11 +_ 2 [6-16] 10 ± 2 [4-17] 0.18 
LVEDV 53 + 9 [27-79] 54 ± 10 [26-82] 57 _+ 1i [27-88] 57 _+ 10 [30-84] 0.02 
PAP 44 _+ 4 [35-53] 35 -+ 4 [24-45] 33 +- 4 [22-44] 33 _+ 4 [21-44] <0.0001 
PVR 10.4 _+ 3 [2.9-18] 7.5 _+ 3 [0.2-15] 6.3 _+ 2 [0.9-12] 6.5 _+ 2 [1-12] 0.0008 
Contractility 
ESPVR 1.8 _+ 0.3 2.2 + 0.7 1.9 _+ 0.5 2.1 _+ 0.5 >0.2 
Mo -6  + 16 -16  _+ 20 -10  _+ 16 -16  ± 20 >0.2 
SWEDV 42 _+ 8 48 _+ 4 49 _+ 4 49 + 5 >0.2 
Vo 24 +_ 13 28 _+ i3 29 _+ 11 29 ± 12 >0.2 
Figures are expressed as mean -+ standard error of the mean. Brackets indicate 95% confidence intervals. CO, Cardiac output (L/min); MAP, mean arterial 
pressure (mm Hg); SVR, systemic vascular resistance (Wood units); LVEDP, left ventricular end-diastolic pressure (mm Hg); LVEDV, left ventricular 
end-diastolid volume; PAP, pulmonary artery pressure (mm Hg); PVR, pulmonary vascular resistance; ESPVR, end-systolic pressure-volume relation (mm 
Hg/ml); Mo, x-axis intercept of ESPVR line (ml); SWEDV, stroke-work end-diastolic volume (erg.cm-3.103) (erg • cm 3. 103); Vo, x-axis intercept of 
SWEDV line (ml). 
0.06). In this group, inhaled NO caused a reduction 
in PA pressure (p < 0.0001) and a reduction of 
pulmonary vascular resistance (p = 0.0008) at all 
three doses. An elevation in LVEDV at all three 
doses of inhaled NO was noted (p = 0.02), whereas 
no change in LVEDP was observed. A trend toward 
increased cardiac output was noted (p = 0.18) 
(Table II). ESPVR and SWEDV again were unaf- 
fected by administration of inhaled NO at any dose. 
Results are summarized in Table II. Comparison of 
ventricular contractility (mean _+ standard error of 
the mean) before and after induction of pulmonary 
hypertension was ESPVR 2.03 _+ 0.73 (1.25 to 2.8, 
95% CI) versus 1.81 _+ 0.32 (0.39 to 4.66, 95% CI), 
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p = 0.39, and SWEDV 56.7 _+ 6 (41.1 to 71.2, 95% 
CI) versus 47.4 +_ 6 (31.8 to 62.9, 95% CI),p = 0.2. 
Discussion 
The results of this study demonstrate hat inhaled 
NO does not lead to alterations in LV contractile 
state. In fact, the only observed hemodynamic alter- 
ations associated with inhaled NO were reductions 
in PA pressure and pulmonary vascular esistance 
and a mild elevation in LVEDV. These findings are 
consistent with other reports of the hemodynamic 
effects of inhaled NO and further clarify the mech- 
anism by which elevations in pulmonary capillary 
wedge pressure occur during this therapy. 
Inhaled NO is currently an important therapy in a 
number of clinical situations for both diagnostic and 
therapeutic purposes. Inhaled NO is being used to 
test vasoreactivity in patients with heart failure 
during evaluation for cardiac transplantationl:; 
fixed pulmonary hypertension is considered a con- 
traindication for transplantation because of the 
prevalence of perioperative right heart failure 18' 19 
Inhaled NO is also being used with increasing 
frequency in the perioperative management of right 
heart failure in patients undergoing heart ransplan- 
tation or LV assist device implantation, e°
Several :reports of acute elevation in pulmonary 
artery wedge pressure in the heart failure popula- 
tions have been published, 6' 10, 11 and concern has 
emerged that the increase in LV filling pressure 
reflects negative inotropic actions of this therapy. 
This concern has been bolstered by laboratory re- 
ports of negative inotropic actions of NO in isolated 
myocyte preparations. 7-9 However, NO is rapidly 
sequestered byhemoglobin i  the blood and thereby 
should be inactivated long before reaching the sys- 
temic circulation, el This rapid sequestration is sup- 
ported by the lack of systemic vasodilatory effects in 
the setting of significant pulmonary vasodilation. It
is therefore unlikely that when administered via the 
inhaled route, NO could exert any direct myocardial 
effects, ee'e3 In fact, results of the present study 
failed to show any effects of inhaled NO on LV 
contractile function. 
The mechanism by which inhaled NO leads to 
elevations in LV filling pressure remains to be 
answered. We observed an increase in LVEDV in 
response to pulmonary vasodilation and showed that 
this increase is not due to alterations in ventricular 
function. This finding is consistent with a recent 
theoretic analysis of the direct impact of pulmonary 
vasodilation on pulmonary venous pressure. 24 In 
this study, Dickstein and Burkhoff 24 showed that 
progressive pulmonary vasodilation is associated 
with increases in pulmonary wedge pressure inde- 
pendent of changes in ventricular function. Impor- 
tantly, it was also shown that the magnitude of 
increase in pulmonary wedge pressure was most 
affected by intravascular volume. The present study 
was conducted under euvolemic onditions, and we 
still observed increases in LVEDV. Operating on 
the flat portion of the normal diastolic compliance 
curve, it is not surprising that we observed no 
significant increase in LVEDP. It is likely that with 
larger intravascular volumes and/or operating on the 
steeper portion of a diastolic compliance curve, the 
increases in LVEDP relative to LVEDV would be 
more profound. 
In summary, we have demonstrated that inhaled 
NO therapy does not affect he inotropic state of the 
normal myocardium. Under conditions of pulmo- 
nary hypertension and an intact LV, inhaled NO 
therapy produces elective pulmonary vasodilation 
and does not affect myocardial contractile perfor- 
mance. The rise in left atrial pressure in patients 
with preexisting LV dysfunction receiving inhaled 
NO therapy appears to be a direct consequence of
pulmonary vasodilation. 
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